Tag: 100-200

On March 3, 1998, Kanda, Yoichi; Saito, Koki; Sato, Tsutomu published a patent.Application of 90764-84-4 The title of the patent was Preparation of N-(phenylsulfonyl)picolinamides and herbicides containing them. And the patent contained the following:

Title compounds I [X = halo, C1-4 (halo)alkyl, C1-4 (halo)alkoxy, (C1-4 alkoxy)carbonyl, (di)(C1-4 alkyl)aminosulfonyl, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, NO2; Y = halo, C1-4 (halo)alkyl, C1-4 (halo)alkoxy, C1-4 (halo)alkylthio, NH2, (di)(C1-4 alkyl)amino, (C1-4 alkoxy)(C1-4 alkyl), (C1-4 alkylthio)(C1-4 alkyl), NO2; m = 0-4; n = 0-5], useful as herbicides, are prepared by (A) condensation of picolinic acids II (R = H; Y, m = same as I) with XnC6H5-nSO2NH2 (III; X, n = same as I) or (B) reaction of II (R = C6H5-sZs; Z = halo, C1-4 alkyl, C1-4 alkoxy, NO2; s = 0-5) with III in the presence of bases. III (Xn = 2,6-Cl2) was treated with NaH in DMF and treated with II (R = Ph, Ym = 5-OMe-6-Cl) at 70° for 1 h to give 70.7% I (Xn = 2,6-Cl2, Ym = 5-OMe-6-Cl). Herbicidal activity of I was tested for 11 kinds of weeds. The experimental process involved the reaction of 4,6-Dimethoxypicolinic acid(cas: 90764-84-4).Application of 90764-84-4

The Article related to picolinamide phenylsulfonyl preparation herbicide, benzenesulfonamide amidation picolinic acid, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application of 90764-84-4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 16, 2008, Ashweek, Neil; Chen, Mi; Coon, Timothy Richard; Ewing, Todd; Jiang, Wanlong; Moree, Willy; Rowbottom, Martin; Wade, Warren; Zhao, Liren; Zhu, Yun-Fei; Yu, Jinghua; Beaton, Graham published a patent.Related Products of 156267-13-9 The title of the patent was Preparation of benzenesulfonylamide derivatives as Gonadotropin-releasing hormone receptor antagonists. And the patent contained the following:

Title compounds represented by the formula I [wherein A = pyridyl, Ph, quinolinyl, etc.; R1a = H, halo, alkyl, etc.; R1b, R1c = independently H, halo, OH, etc.; R1d = F, Cl, Me, CF3 or cyano; R2 = alkyl-(R5)p; R2a = (un)substituted Ph, aryl, alkyl, etc.; or R2R2a = (un)substituted heterocycle; R5 = independently H, OH, amino, etc.; p = 1-3; and stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof] were prepared as Gonadotropin-releasing hormone receptor (GnRH) antagonists. For example, II was provided in a multi-step synthesis starting from 1-bromo-2-chloro-4-fluorobenzene. I were tested in one or more of the peptide competitive human receptor binding assays and showed Ki values of 1 μM or less. Thus, I and their pharmaceutical compositions are useful for the treatment of a variety of sex-hormone related conditions in both men and women. The experimental process involved the reaction of N,3-Dimethylpyridin-2-amine(cas: 156267-13-9).Related Products of 156267-13-9

The Article related to benzenesulfonylamide pyridinyl preparation gonadotropin releasing hormone receptor antagonist, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Related Products of 156267-13-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 16, 2008, Beaton, Graham; Chen, Mi; Coon, Timothy Richard; Ewing, Todd; Jiang, Wanlong; Lowe, Richard; Moree, Willy; Smith, Nicole; Wade, Warren; Zhao, Liren; Zhu, Yun-Fei; Rowbottom, Martin; Ashweek, Neil published a patent.Synthetic Route of 156267-13-9 The title of the patent was Preparation of benzenecarboxamide derivatives as Gonadotropin-releasing hormone receptor antagonists. And the patent contained the following:

Title compounds represented by the formula I [wherein A = pyridyl, Ph, quinolinyl, etc.; R1a = H, halo, alkyl, etc.; R1b, R1c = independently H, halo, OH, etc.; R1d = F, Cl, Me, CF3 or cyano; R2 = alkyl-(R5)p; R2a = (un)substituted Ph, (hetero)aryl or alkyl; R5 = independently H, OH, amino, etc.; p = 1-3; and stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof] were prepared as Gonadotropin-releasing hormone receptor (GnRH) antagonists. For example, II was provided in a multi-step synthesis starting from 3-bromo-4-chlorobenzoic acid. I were tested in one or more of the peptide competitive human receptor binding assays and showed Ki values of 1 μM or less. Thus, I and their pharmaceutical compositions are useful for the treatment of a variety of sex-hormone related conditions in both men and women. The experimental process involved the reaction of N,3-Dimethylpyridin-2-amine(cas: 156267-13-9).Synthetic Route of 156267-13-9

The Article related to benzenecarboxamide pyridinyl preparation gonadotropin releasing hormone receptor antagonist, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Synthetic Route of 156267-13-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 31, 1974, Fleckenstein, Erwin; Heinrich, Ernst; Mohr, Reinhard published a patent.HPLC of Formula: 51566-22-4 The title of the patent was Pyridine derivatives. And the patent contained the following:

Pyridine derivatives I (R and R1 = amino, alkoxy, alkylthio, CN, Cl) (642 compounds) were prepared by substitution reactions on I (R = R1 = Cl). The experimental process involved the reaction of 3-Methylpyridine-2,6-diamine(cas: 51566-22-4).HPLC of Formula: 51566-22-4

The Article related to pyridine dichloro substitution, substitution dichloropyridine, dye intermediate poridine, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 51566-22-4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 31, 2015, Lebedeva, O. V.; Chesnokova, A. N.; Badlueva, T. V.; Sipkina, E. I.; Rzhechitskii, A. E.; Pozhidaev, Yu. N. published an article.Reference of Pyridine-3-sulfonic acid The title of the article was Hybrid ion-exchange membranes based on heteroaromatic sulfonic acid derivatives. And the article contained the following:

Membranes exhibiting proton conductivity have been prepared by sol-gel synthesis using tetraethoxysilane and heteroaromatic sulfonic acid derivatives (2-phenyl-5-benzimidazolesulfonic acid and 3-pyridinesulfonic acid) in the presence of phosphoric acid and polyvinyl butyral. The membranes are gels composed of a polyvinyl butyral polymer matrix with uniformly distributed particles of silica containing mols. of heteroaromatic sulfonic acid derivatives mech. incorporated in its network structure. The membranes synthesized from 2-phenyl-5-benzimidazolesulfonic acid or 3-pyridinesulfonic acid exhibit a conductivity of 0.1X10-2 or 0.55X10-2 S/cm at 353 K, an ion-exchange capacity of 2.70 or 1.84 mequiv/g, and a proton-transfer activation energy of 24.93 or 21.73 kJ/mol, resp.; at a relative water content of 50%, the tensile strength is 4 or 6 MPa and the elastic modulus is 128 or 191 MPa, resp. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Reference of Pyridine-3-sulfonic acid

The Article related to tetraethoxysilane heteroaromatic sulfonic acid derivative membrane mech elec property, Plastics Fabrication and Uses: Plastic Product Uses and other aspects.Reference of Pyridine-3-sulfonic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 21, 2018, Wang, Xiaoqin; Zhao, Chuping; He, Minghua; Zhong, Zhiqian; Chen, Jiahe; Wang, Yanchun; Wang, Maoqin published a patent.Formula: C10H10N4 The title of the patent was Preparation of 3,3′-disubstituted bipyridine derivative as anti-Alzheimer’s disease drug. And the patent contained the following:

This invention provides 3,3′-disubstituted dipyridine derivatives I and II [wherein R = H, OH, halo, etc.; R1 = O(CH2)mCH3 or OH; m and n = independently 0-3; R2 = alkyl, one or more Me or Et substituted amino, etc.]. The title compounds can be used in preparing drugs for prevention and/or treatment of Alzheimer’s disease, vascular dementia or myasthenia gravis disease. The invention has the advantages of low biotoxicity, good safety, and broad application space in preparing anti-Alzheimer’s disease drugs. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Formula: C10H10N4

The Article related to bipyridine treatment alzheimer disease vascular dementia myasthenia gravis human, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Formula: C10H10N4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Van der Does, L.; Den Hertog, H. J. published an article in 1972, the title of the article was Didehydrohetarenes. XXV. Amination of alkyl substituted halopyridines with potassium amide in liquid ammonia.Quality Control of 6-(tert-Butyl)pyridin-3-amine And the article contains the following content:

The action of KNH2 in liquid NH3 on Me substituted 3- and 4-bromo(or chloro)pyridines, of 5-bromo-2-tert-butylpyridine and of 3-bromo(or chloro) and 4-bromo(or chloro)-2,6-dimethylpyridine was studied. The results of the reactions indicate the occurrence of derivatives of 3,4-didehydropyridine as intermediates. An interpretation is given of the influence of the substituent and the hetero atom on the course of the aminations. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Quality Control of 6-(tert-Butyl)pyridin-3-amine

The Article related to hetarene didehydro, amination alkylhalopyridine, pyridine alkylhalo amination, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Quality Control of 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 20, 2008, Glatthar, Ralf; Johns, Donald; Umbricht, Daniel published a patent.Application of 85614-89-7 The title of the patent was Preparation of pyridine derivatives as modulators of metabotropic glutamate receptors. And the patent contained the following:

Title compounds represented by the formula I [wherein R1 – (un)substituted alkyl or benzyl; R2 = H, alkyl or (un)substituted benzyl; or R1R2N = (un)substituted heterocyclyl; R3 = halo, alkoxy, alkyl(amino) or dialkylamino; R4 = OH, halogen, alkyl or alkoxy; Q = CH, CR4 or N; V = CH, CR4 or N; W = CH, CR4 or N; X = CH or N; Y = CH, CR3 or N; Z = CH2, NH or O; provided that Q, V and W are not N at the same time; and in free base or acid addition salt form] were prepared as metabotropic glutamate receptors (mGluR) antagonist, especially mGluR5 antagonist,. For example, reaction of 6-chloro-N,N-diethylnicotinamide with 4-chloroaniline gave II in 56% yield. I were tested for inhibition of the glutamate induced elevation of intracellular Ca2+-concentration at a concentration of 10 μM, and I were also in clin. testing. Thus, I and their pharmaceutical compositions are useful as mGluR modulator for the treatment, prevention or delay of progression of cognitive dysfunction. The experimental process involved the reaction of Ethyl 5-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate(cas: 85614-89-7).Application of 85614-89-7

The Article related to pyridine derivative preparation metabotropic glutamate receptor modulator, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application of 85614-89-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Xin, Xia; Pietraszkiewicz, Marek; Pietraszkiewicz, Oksana; Chernyayeva, Olga; Kalwarczyk, Tomasz; Gorecka, Ewa; Pociecha, Damian; Li, Hongguang; Holyst, Robert published an article in 2012, the title of the article was Eu(III)-coupled luminescent multi-walled carbon nanotubes in surfactant solutions.Synthetic Route of 75449-26-2 And the article contains the following content:

A carbon nanotube/inorganic hybrid material was fabricated by coupling Eu(III) complexes onto multi-walled carbon nanotubes (MWCNTs). Successful coupling was verified by XPS measurement where a clear signal from Eu3d was identified. When sonicated in hexaethylene glycol monododecyl ether (C12E6) or sodium dodecyl sulfate (SDS) aqueous solutions, the MWCNTs with Eu-complex attached (denoted as Eu-MWCNTs hereafter) can be dispersed. UV-visible measurements on a dilute dispersion of Eu-MWCNTs in SDS aqueous solution reveal the characteristic absorption from Eu(III) complexes, which gives further proof of the successful coupling. The strong luminescent properties of Eu-MWCNTs allow them to be observed directly under a fluorescence microscope. Eu-MWCNTs can undergo continuous movements in C12E6 or SDS dilute solutions When Eu-MWCNTs are incorporated into the lyotropic liquid crystal phase formed by C12E6 (above 40% by weight), however, movements were hindered. Small angle x-ray scattering measurements showed that Eu-MWCNTs are ordered in the lyotropic liquid crystal. Fluorescence microscopy observations reveal that the luminescent properties of the Eu-MWCNTs were not affected by the liquid crystalline surfactant matrix. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Synthetic Route of 75449-26-2

The Article related to carbon nanotube dispersion surfactant luminescence solution, Surface Chemistry and Colloids: Solid-Liquid Systems and other aspects.Synthetic Route of 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 21, 2022, Gavory, Gerald; Ghandi, Mahmoud; Chicas, Agustin; Warmuth, Markus published a patent.HPLC of Formula: 39919-70-5 The title of the patent was Preparation of isoindolinone compounds for treating Myc-driven cancers with GSPT1 degraders. And the patent contained the following:

The present disclosure relates to new methods to predict the responsiveness of cancer patients to GSPT1 neg. modulators and thus determine the of efficacy GSPT1 neg. modulators to treat cancer patients by determining the level of one or more biomarkers in samples of the patients. The present disclosure also relates to applications of these methods, which includes stratifying cancer malignancies, in particular identifying Myc-driven cancers, and thereby devising optimized and personalized treatments for these cancer patients, as well as optimizing the selection of patient populations for resp. clin. trials. The title compounds I [X1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; or X1 together with X4 forms (un)substituted 4-8 membered heterocycloalkyl; X2 = H, cycloalkyl, aryl, etc.; X3 = NH, O; X4 = NH, CH2; X5 = H, alkyl, alkoxy, CN, etc.; L1 and L2 = (independently) a covalent bond, (un)substituted alkylene; L3 = a covalent bond, O, (un)substituted alkylene, etc.] or pharmaceutically acceptable salts or stereoisomers thereof, were prepared E.g., a multi-step synthesis of II, starting from Me 5-bromo-2-methylbenzoate, was described. Exemplified compounds I were tested for their ability for cereblon binding (data given for representative compounds I). The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).HPLC of Formula: 39919-70-5

The Article related to isoindolinone dioxopiperidinyl preparation cereblon modulator anticancer myc driven cancer, gspt1 degrader modulator biomaker isoindolinone dioxopiperidinyl preparation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem